Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-26T14:22:30.430Z Has data issue: false hasContentIssue false
  • English
  • Français

Canadian Guidelines for the Development of Antidementia Therapies: a Conceptual Summary

Published online by Cambridge University Press:  18 September 2015

Erich Mohr ,
Howard Feldman  and
Serge Gauthier
Erich Mohr*
Affiliation:
Institute of Mental Health Research, University of Ottawa/Royal Ottawa Hospital, Ottawa Consortium of Canadian Centres for Clinical Cognitive Research, C5R Secretariat at McGill Centre for Stuides in Aging, McGill University, Montreal
Howard Feldman
Affiliation:
University of British Columbia, Division of Neurology, Vancouver Consortium of Canadian Centres for Clinical Cognitive Research, C5R Secretariat at McGill Centre for Stuides in Aging, McGill University, Montreal
Serge Gauthier
Affiliation:
The McGill Centre for Studies in Aging, McGill University, Montreal Consortium of Canadian Centres for Clinical Cognitive Research, C5R Secretariat at McGill Centre for Stuides in Aging, McGill University, Montreal
*
Neuropsychology Lab. Room D733. Ottawa Civic Hospital, 1053 Carling Avenue, Ottawa, Ontario, Canada K1Y4E9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The magnitude of the problems faced by Canadian society as a result of an aging population has been identified. Perhaps the most important concern related to this greying of Canada is the increasing incidence of dementia and Alzheimer’s disease. Therapeutic options for these disorders have been limited to date. Advances in biotechnology and molecular biology will offer novel approaches to treatment. These and the expansion of more traditional therapeutic avenues require guidelines with the aim of optimizing their development.

Type
Neurological Practice
Information
Canadian Journal of Neurological Sciences , Volume 22 , Issue 1 , February 1995 , pp. 62 - 72
Copyright
Copyright © Canadian Neurological Sciences Federation 1995

References

1. Canadian study on health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; (in press).Google Scholar
2. Max, W.The economic impact of Alzheimer’s disease. Neurology 1993; 43 (Suppl. 4): S6-S10.Google Scholar
3. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines, World Health Organization, 1992.Google Scholar
4. Cummings, JL, Benson, DF.Dementia: A Clinical Approach, 2nd edition. Boston: Butterworth-Heinemann 1992: 1–2.Google Scholar
5. American Psychiatric Association, Diagnostic and statistical manual of mental disorders: Revised, 3rd edition. Washington, D.C.: American Psychiatric Association, 1987.Google Scholar
6. Organizing Committee Canadian concensus conference on the Assessment of Dementia. Assessing dementia: the Canadian consensus. Can Med Assoc J 1991; 144: 851–853.Google Scholar
7. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA working group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.CrossRefGoogle Scholar
8. Tierney, MC, Fisher, RH, Lewis, AJ, Zorzitto, ML, Snow, WG, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology 1988; 38: 359–364.CrossRefGoogle ScholarPubMed
9. Joachim, CL, Morris, JH, Selkoe, DJ.Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann Neurol 1988; 24:50–56.CrossRefGoogle ScholarPubMed
10. Poirier, J, Davignon, J, Bouthillier, D, Kogan, S, Bertrand, P, et al. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993; 342:697–699.CrossRefGoogle ScholarPubMed
11. Corder, EH, Saunders, AM, Strittmatter, WJ, Schmechel, DE, Gaskell, PC, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261:921–923.CrossRefGoogle ScholarPubMed
12. Strittmatter, WJ, Saunders, AM, Schmechel, D, Pericak-Vance, M, Enghild, J, et al. Apolipoprotein E: high-affinity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 1977–1981.CrossRefGoogle Scholar
13. Saunders, AM, Strittmatter, WJ, Schmechel, D, George-Hyslop, PH, Pericak-Vance, MA, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43: 1467–1472.CrossRefGoogle ScholarPubMed
14. Selkoe, DJ.Amyloid protein and Alzheimer’s disease. Sci Am 1991; Nov: 54–61.Google ScholarPubMed
15. Selkoe, DJ.In the beginning. Nature 1991; 354: 432–433.CrossRefGoogle Scholar
16. Cai, X-D, Golde, TE, Younkin, SG.Release of excess amyloid B protein from a mutant amyloid B protein precursor. Science 1993; 259:514–516.CrossRefGoogle Scholar
17. Miller, BL, Moats, RA, Shonk, T, Ernst, T, Wooley, S, et al. Alzheimer’s disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993; 187: 433–437.CrossRefGoogle ScholarPubMed
18. Ogomori, K, Kitamoto, T, Tateishi, J, Sato, Y, Suetsugu, M, et al. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer’s disease. Am J Pathol 1989; 134:243–251.Google ScholarPubMed
19. Petit, D, Montplaisir, J, Lorrain, D, Gauthier, S.Spectral analysis of the rapid eye movement sleep electroencephalogram in right and left temporal regions: a biological marker of Alzheimer’s disease. Ann Neurol 1992; 32: 172–176.CrossRefGoogle ScholarPubMed
20. Leuchter, AF, Cook, IA, Newton, TF, Dunkin, J, Walter, DO, et al. Regional differences in brain electrical activity in dementia: use of spectral power and spectral ratio measures. Electroencephalogram Neurophysiol 1993; 87: 385–393.CrossRefGoogle ScholarPubMed
21. Katzman, R.Alzheimer’s disease. N Eng J Med 1986; 314: 964–973.CrossRefGoogle ScholarPubMed
22. Katzman, R.Differential diagnosis of dementing illnesses. Neurol Clin 1986; 4:329–340.CrossRefGoogle ScholarPubMed
23. Hachinski, VC, Lassen, NA, Marshal, J.Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet 1974; 2: 207–210.CrossRefGoogle ScholarPubMed
24. Rosen, WG, Terry, RD, Fuld, PA, Katzman, R, Peck, A.Pathological verification of ischemic score in differentiation of dementia. Ann Neurol 1980; 7:486–488.CrossRefGoogle Scholar
25. Roman, GC, Tatemichi, TK, Erkinjuntti, T, Cummings, JL, Masdeu, JC, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–260.CrossRefGoogle ScholarPubMed
26. Chui, HC, Victoroff, JI, Margolin, D, Jagust, W, Shankle, R, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 1992; 42: 473–480.CrossRefGoogle ScholarPubMed
27. Erkinjuntti, T, Haltia, M, Palo, J, Sulkava, R, Paetau, A.Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study. J Neurol Neurosurg Psychiatry 1988; 51: 1037–1044.CrossRefGoogle ScholarPubMed
28. Burkhardt, CR, Filley, CM, Kleinschmidt-DeMasters, BK, De la Monte, S, Norenberg, MD, et al. Diffuse Lewy body disease and progressive dementia. Neurology 1988; 38:1520–1528.CrossRefGoogle ScholarPubMed
29. Edwards, RJ, McKenzie, JE, Roberts, GW, Royston, MC.Alzheimer’s disease and Lewy body dementia. Br J Psychiatry 1993; 163:692.CrossRefGoogle ScholarPubMed
30. Litvan, I, Mohr, E, Williams, J, Gomez, C, Chase, TN.Differential memory and executive functions in demented patients with Parkinson’s and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1991; 54:25–29.CrossRefGoogle ScholarPubMed
31. Mohr, E, Mendis, T, Grimes, JD.Late cognitive changes in Parkinson’s disease with an emphasis on dementia. In: Weiner, WJ, Lang, AE, eds. Behavioral Neurology of Movement Disorders. New York, Raven Press, 1994.Google Scholar
32. Gustafson, L.Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia 1993; 4: 143–148.Google ScholarPubMed
33. Clinton, J, Mann, DMA, Roberts, GW.Frontal lobe dementia is not a variant of prion disease. Neurosci Lett 1993; 164: 1–4.CrossRefGoogle Scholar
34. Purdon, SE, Mohr, E, llivitsky, V, Jones, BD.Huntington’s disease: pathogenesis, diagnosis, and treatment. J Psychiatr Neurosci 1994; (in press).Google ScholarPubMed
35. Maj, M.Organic mental disorders in HIV-1 infection. AIDS 1990; 4:831–840.CrossRefGoogle ScholarPubMed
36. Reinvang, I, Froland, SS, Skripeland, V.Prevalence of neuropsychological deficit in HIV infection. Incipient signs of AIDS dementia complex in patients with AIDS. Acta Neurol Scand 1991; 83: 289–293.CrossRefGoogle ScholarPubMed
37. Reisberg, B, Ferris, SH, De Leon MJ, Crook, T.The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–1139.Google ScholarPubMed
38. Berg, L.Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988; 24:637–639.Google ScholarPubMed
39. Hughes, CP, Berg, L, Danziger, WL, Coben, LA, Martin, RL.A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–572.CrossRefGoogle ScholarPubMed
40. Reisberg, B, Ferris, SH, De Leon, MJ, Crook, T.Global Deterioration Scale (GDS). Psychopharmacol Bull 1988; 24: 661–663.Google ScholarPubMed
41. Crockett, D, Tuokko, H, Koch, W.The assessment of everyday functioning using the present functioning questionaire and the Functional Rating Scale in elderly subjects. Clin Gerontol 1989; 8: 3–23.CrossRefGoogle Scholar
42. Mayeux, R, Stern, Y, Spanton, S.Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985; 35: 453–461.CrossRefGoogle ScholarPubMed
43. Mann, UM, Mohr, E, Chase, TN.Rapidly progressive Alzheimer’s disease. Lancet 1989; 2: 799.CrossRefGoogle ScholarPubMed
44. Mohr, E, Mann, UM, Chase, TN.Subgroups in Alzheimer’s disease: fact or fiction. Psychiatr J Univ Ott 1990; 15: 203–206.Google ScholarPubMed
45. Weinstein, HC, Hijdra, A, Van Royen EA, Derix, MMA, Walstra, G, et al. SPECT in early- and late-onset Alzheimer’s disease. Ann N Y Acad Sci 1991; 640: 72–73.CrossRefGoogle ScholarPubMed
46. Haupt, M, Kurz, A, Pollmann, S.Severity of symptoms and rate of progression in Alzheimer’s disease: a comparison of cases with early and late onset. Dementia 1992; 3: 21–24.Google Scholar
47. Mann, UM, Mohr, E, Gearing, M, Chase, TN.Heterogeneity in Alzheimer’s disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry 1992; 55: 956–959.CrossRefGoogle ScholarPubMed
48. Yesavage, JA, Brooks, JO. III, Taylor, J, Tinklenberg, J.Development of aphasia, apraxia, and agnosia and decline in Alzheimer’s disease. Am J Psychiatry 1993; 150: 742–747.Google ScholarPubMed
49. Feldman, H, Weir, J, Bell, K, Beattie, BL.Extrapyramidal signs (EPS) in Alzheimer’s disease: do they predict the rate of decline? Gerontologist 1993; 33: 176–177. (Abstract)Google Scholar
50. Mayeux, R, Stern, Y, Sano, M.Heterogeneity and prognosis in dementia of the Alzheimer type. Bull Clin Neurosciences 1985; 50:7–10.Google ScholarPubMed
51. Stern, Y, Mayeux, R, Sano, M, Hauser, WA, Bush, T.Predictors of disease course in patients with probable Alzheimer’s disease. Neurology 1987; 37: 1649–1653.CrossRefGoogle ScholarPubMed
52. Morris, JC, Edland, S, Clark, C, Galasko, D, Koss, E, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology 1993; 43: 2457–2465.CrossRefGoogle Scholar
53. Morris, JC, Heyman, A, Mohs, RC, Hughes, JP, Van Belle G, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989; 39: 1159–1165.Google Scholar
54. Skoog, I, Nilsson, L, Palmertz, B, Andreasson, LA, Svanborg, A.A population-based study of dementia in 85-year-olds. N Engl J Med 1993; 328: 153–158.CrossRefGoogle ScholarPubMed
55. Osuntokun, BO, Ogunniyi, AO, Lekwauwa, GU, Oyediran, AB.Epidemiology of age-related dementias in the Third World and aetiological clues of Alzheimer’s disease. Trop Geograph Med 1991; 43:345–351.Google ScholarPubMed
56. Waters, C.Cognitive enhancing agents: current status in the treatment of Alzheimer’s disease. Can J Neurol Sci 1988; 15: 249–256.CrossRefGoogle ScholarPubMed
57. Claus, JJ, Ludwig, C, Mohr, E, Giuffra, M, Blin, J, et al. Nootropic drugs in Alzheimer’s disease: symptomatic treatment with pramiracetam. Neurology 1991; 41: 570–574.CrossRefGoogle ScholarPubMed
58. Mohs, RC, Rosen, WG, Davis, KL.The Alzheimer’s Disease Assessment Scale: an instrument of assessing treatment efficacy. Psychopharmacol Bull 1983; 19: 448–450.Google ScholarPubMed
59. Rosen, WG, Mohs, RC, Davis, KL.A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–1364.Google ScholarPubMed
60. Mohr, E, Walker, D, Randolph, C, Sampson, M, Wesnes, K, et al. The utility of clinical trial batteries in the evaluation of dementia of different etiologies. Submitted 1994.Google Scholar
61. Randolph, C.Repeatable Battery for the Assessment of Dementia (RBAD). (In Press), New York: Psychological Corporation, 1994.Google Scholar
62. Walker, D.Distinguishing Huntington’s dementia from Alzheimer’s dementia in clinical trial batteries. Ottawa: M.A. Thesis, Carleton University, 1992.Google Scholar
63. Wesnes, K.A fully automated psychometric test battery for human psychopharmacology. In: Abstracts of the IVth World Congress of Biological Psychiatry. Philadelphia, 1985: 153.Google Scholar
64. Albert, M, Cohen, C.The test for severe impairment: an instrument for the assessment of patients with severe cognitive dysfunction. Am Geriatr Soc 1992; 40: 449–453.CrossRefGoogle ScholarPubMed
65. Sclan, SG, Reisberg, B.Functional assessment staging (FAST) in Alzheimer’s disease: reliability, validity, and ordinality. Internat Psychogeriatr 1992; 4 (Suppl 1): 55–69.CrossRefGoogle ScholarPubMed
66. Saxton, J, Swihart, AA.Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med 1989; 5: 531–543.CrossRefGoogle ScholarPubMed
67. Panisset, M, Roudier, M, Saxton, J, Boiler, F.A battery of neuropsychological tests for severe dementia. An evaluation study. [French]. Presse Medicale – Paris 1992; 21: 1271–1274.Google ScholarPubMed
68. Reisberg, B, Borenstein, J, Salob, SP, Ferris, SH, Franssen, E, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (Suppl 5): 9–15.Google ScholarPubMed
69. Reisberg, B, Borenstein, J, Franssen, E.Behav-AD: A clinical rating scale for the assessment of pharmacologically remediable behavioral symptomatology in Alzheimer’s disease. In: Altman, HJ, ed. Alzheimer’s disease: Problems, Prospects and Perspectives. New York, Plenum Press, 1987.Google Scholar
70. O’Leary, PA, Haley, WE, Paul, PB.Behavioral assessment in Alzheimer’s disease: use of a 24-hr log. Psychol Aging 1993; 8: 139–143.CrossRefGoogle ScholarPubMed
71. Krai, VA.The relationship between senile dementia (Alzheimer type) and depression. Can J Psychiatry 1983; 28: 304–306.Google Scholar
72. Ron, MA, Toone, BK, Garralda, ME, Lishman, WA.Diagnosis accuracy in presenile dementia. Br J Psychiatry 1979; 134: 161–168.CrossRefGoogle ScholarPubMed
73. Liston, EH.Diagnostic delay in presenile dementia. J Clin Psychiatry 1978; 39: 599–603.Google ScholarPubMed
74. Lazarus, LW, Newton, N, Cohler, B, Lesser, J, Schweon, C.Frequency and presentation of depressive symptoms in patients with primary degenerative dementia. Am J Psychiatry 1987; 144: 41–45.Google ScholarPubMed
75. Hamilton, M.A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.CrossRefGoogle ScholarPubMed
76. Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J.An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.CrossRefGoogle ScholarPubMed
77. Alexopoulos, GS, Abrams, RC, Young, RC, Shamoian, CA.Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271–284.CrossRefGoogle ScholarPubMed
78. Drevets, WC, Rubin, EH.Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989; 25:39–48.CrossRefGoogle ScholarPubMed
79. Gauthier, L, Gauthier, S.Assessment of functional changes in Alzheimer’s disease. Neuroepidemiology 1990; 9: 183–188.CrossRefGoogle ScholarPubMed
80. Linn, MW, Linn, BS.The rapid disability rating scale. Part 2. J Am Geriatr Soc 1982; 30:378–382.CrossRefGoogle Scholar
81. Lawton, MP, Brody, EM.Assessment of older people: self-maintaining and instrumental activities. Gerontologist 1969; 9: 179–186.CrossRefGoogle ScholarPubMed
82. Gauthier, L., Gauthier, S., Gelinas, I., Mclntyre, M., Wood-Dauphinee, S.Assessment of functioning and ADL. Berlin: Sixth Congress of the I PA, 1993.Google Scholar
83. Rockwood, K.Use of global assessment measures in dementia drug trials. J Clin Epidemiol 1994; 47: 101–103.CrossRefGoogle ScholarPubMed
84. Cutler, NR, Haxby, JV, Duara, R, Grady, CL, Kay, AD, et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer’s disease. Ann Neurol 1985; 18: 298–309.CrossRefGoogle ScholarPubMed
85. Friedland, RP, Budinger, TF, Ganz, E, Yano, Y, Mathis, CA, et al. Regional cerebral metabolic alternations in dementia of the Alzheimer type: positron emission tomography with (18F) Fluorodeoxyglucose. J Comput Assist Tomogr 1983; 7: 590–598.CrossRefGoogle Scholar
86. McGeer, EG, Peppard, RP, McGeer, PL, Tuokko, H, Crockett, D, et al. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can J Neurol Sci 1990; 17: 1–11.CrossRefGoogle ScholarPubMed
87. Foster, NL, Chase, TN, Fedio, P, Patronas, NJ, Brooks, RA, et al. Alzheimer’s disease: focal cortical changes shown by positron emission tomography. Neurology 1983; 33: 961–965.CrossRefGoogle ScholarPubMed
88. Heiss, WD, Szelies, B, Kessler, J, Herholz, K.Abnormalities of energy metabolism in Alzheimer’s disease studies with PET. Ann N Y Acad Sci 1991; 640:65–71.CrossRefGoogle ScholarPubMed
89. Frackowiak, RSJ, Pozzilli, C, Legg, NJ.Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981; 104: 753–778.CrossRefGoogle ScholarPubMed
90. Brun, A, Englund, E.Regional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549–564.CrossRefGoogle ScholarPubMed
91. Friedland, RP, Brun, A, Budinger, TF.Pathological and positron emission tomographic correlations in Alzheimer’s disease. Lancet 1985; 1 (8422): 228.CrossRefGoogle ScholarPubMed
92. Goto, I, Taniwaki, T, Hosokawa, S, Otsuka, M, Ichiya, Y, et al. Positron emission tomographic (PET) studies in dementia. J Neurol Sci 1993; 114: 1–6.CrossRefGoogle ScholarPubMed
93. Haxby, JV, Duara, R, Grady, CL, Cutler, NR, Rapoport, SI.Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer’s disease. J Cereb Blood Flow Metab 1985; 5: 193–200.CrossRefGoogle ScholarPubMed
94. Heiss, WD, Kessler, J, Szelies, B, Grond, M, Fink, G, et al. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm 1991; Suppl 33: 13–19.Google ScholarPubMed
95. Leiderman, DB, Balish, M, Bromfield, EB, Theodore, WH.Effect of valproate on human cerebral glucose metabolism. Epilepsia 1991; 32:417–422.CrossRefGoogle ScholarPubMed
96. London, ED.Studies of sigma receptors and metabolic responses to sigma ligand in the brain. NIDA Res Monogr 1993; 133: 55–68.Google Scholar
97. Theodore, WH, Leiderman, D, Gaillard, W, Khan, I, Reeves, P, et al. The effect of naloxone on cerebral blood flow and glucose metabolism in patients with complex partial seizures. Epilepsy Res 1993; 16:51–54.CrossRefGoogle ScholarPubMed
98. Grasby, PM, Friston, KJ, Bench, C, Cowen, PJ, Frith, CD, et al. Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man. Psychopharmacology 1992; 108: 380–386.CrossRefGoogle ScholarPubMed
99. Baxter, LR Jr. Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15: 871–884.CrossRefGoogle ScholarPubMed
100. Baxter, LR Jr., Schwartz, JM, Bergman, KS, Szuba, MP, Guze, BH, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 681–689.CrossRefGoogle ScholarPubMed
101. Ohyama, M, Senda, M, Kitamura, S, Terashi, A.Changes in regional cerebral blood flow during auditory cognitive tasks – a PET activation study with odd-ball paradigm. Rinsho Shinkeigaku 1993; 33: 134–140.Google ScholarPubMed
102. Grady, CL, Haxby, JV, Horwitz, B, Gillette, J, Salerno, JA, et al. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol Aging 1993; 14: 35–44.CrossRefGoogle ScholarPubMed
103. Heiss, W-D, Pawlik, G, Holthoff, V, Kessler, J, Szelies, B.PET correlates of normal and impaired memory functions. Cerebrovasc Brain Metab Rev 1992; 4: 1–27.Google ScholarPubMed
104. Friston, KJ, Grasby, PM, Bench, CJ, Frith, CD, Cowen, PJ, et al. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci Lett 1992; 141: 106–110.CrossRefGoogle ScholarPubMed
105. Friston, KJ, Grasby, PM, Frith, CJ, Bench, CJ, Dolan, RJ, et al. The neurotransmitter basis of cognition: psychopharmacological activation studies using positron emission tomography. Ciba Found Symp 1991; 163:76–87.Google ScholarPubMed
106. Heiss, WD, Kessler, J, Slansky, I, Mielke, R, Szelies, B, et al. Activation PET as an instrument to determine therapeutic efficacy in Alzheimer’s disease. Ann N Y Acad Sci 1993; 659: 327–331.CrossRefGoogle Scholar
107. Shinotoh, H, Asahina, M, Inoue, O, Suhara, T, Hirayama, K, et al. Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography. J Neural Transm [P-D Sect] 1993; 93: 102–110.Google Scholar
108. Karbe, H, Wienhard, K, Harnacher, K, Huber, M, Herholz, K, et al. Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm 1991; 86: 163–173.CrossRefGoogle ScholarPubMed
109. Jagust, WJ, Budinger, TF, Reed, BR.The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 1987; 44:258–262.CrossRefGoogle ScholarPubMed
110. Weinberger, DR, Jones, DW, Sunderland, T, Lee, KS, Sexton, R, et al. In vivo imaging of cerbral muscarinic receptors with 1–123 QNB and SPECT: studies in normal subjects and patients with dementia. Clin Neuropharmacol 1992; 15 Suppl 1 Pt A: 194A-195A.CrossRefGoogle Scholar
111. Binder, JR, Rao, SM, Hammeke, TA, Yetkin, YZ, Wong, EC, et al. Functional magnetic resonance imaging (FMRI) of auditory semantic processing. Neurology 1993; 43 (Suppl 2): A189.Google Scholar
112. Coben, L, Danziger, W, Storandt, M.Longitudinal EEG study of mild senile dementia of Alzheimer type: changes at 1 and 2–5 years. Electroencephalogr Clin Neurophysiol 1985; 61: 101–112.CrossRefGoogle ScholarPubMed
113. Coben, L, Chi, D, Snyder, A, Storandt, M.Replication of a study of frequency analysis of the resting awake EEG in mild probable Alzheimer’s disease. Electroencephalogr Clin Neurophysiol 1990; 75: 148–154.CrossRefGoogle ScholarPubMed
114. Prinz, P, Vitiello, M.Dominant occipital (alpha) rhythm in early stage Alzheimer’s disease and depression. Electroencephalogr Clin Neurophysiol 1989; 73: 427–432.CrossRefGoogle ScholarPubMed
115. Breslav, J, Starr, A, Sicotte, N, Higa, J, Buchsbaum, M.Topographic EEG changes with normal aging and SDAT. Electroencephalogr Clin Neurophysiol 1989; 72: 282–289.Google Scholar
116. Martin-Loeches, M, Gil, P, Jimenez, F, Expósito F, Miguel, F, et al. Topographie maps of brain electrical activity in primary degenerative dementia of the Alzheimer type and multi-infarct dementia. Biol Psychiatry 1991; 29: 211–223,CrossRefGoogle Scholar
117. Duffy, F, Albert, M, McAnulty, G.Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type. Ann Neurol 1984; 16: 439–448.CrossRefGoogle ScholarPubMed
118. Pennttila, M, Partener, V, Soininen, H, Riekkinen, P.Quantitative analysis of occipital EEG in different stages of Alzheimer’s disease. Electroencephalogr Clin Neurophysiol 1991; 78: 89–96.Google Scholar
119. Soininen, H, Partanen, J, Laulumaa, V, Helkala, E, Laakso, M, et al. Longitudinal EEG spectral analysis in early stage Alzheimer’s disease. Electroencephalogr Clin Neurophysiol 1989; 72: 290–297.CrossRefGoogle Scholar
120. Coben, LA, Danziger, WL, Berg, L.Frequency analysis of the resting awake EEG in mild senile dementia of the Alzheimer type. Electroencephalogr Clin Neurophysiol 1983; 55: 372–380.CrossRefGoogle Scholar
121. Schreiter-Gasser, U, Gasser, T, Ziegler, P.Quantitative EEG analysis in early onset Alzheimer’s disease: a controlled study. Electroencephalogr Clin Neurophysiol 1993; 86: 15–22.CrossRefGoogle ScholarPubMed
122. Ihl, R, Maurer, K, Dierks, T, Frlich, L, Perisic, I.Staging in dementia of the Alzheimer type: topography of electrical brain activity reflects the severity of the disease. Psychiatry Res 1989; 29: 399–401.CrossRefGoogle ScholarPubMed
123. Soininen, H, Partanen, J, Páákkõnen A, Koivisto, E, Riekkinen, PJ.Changes in absolute power values of EEG spectra in the follow-up of Alzheimer’s disease. Acta Neurol Scand 1991; 83: 133–136.CrossRefGoogle ScholarPubMed
124. Mohr, E, Knott, V, Mendis, T.Cycloserine treatment in Alzheimer’s disease. Neuropsychopharmacology 1993; 9: 96. (Abstract)Google Scholar
125. Herrmann, WM, Irrgang, U.An absolute must in clinico-pharmacological research: pharmaco-electroencephalography, its possibilities and limitations. Pharmacopsychiatry 1983; 16: 134–142.CrossRefGoogle ScholarPubMed
126. Agnoli, A, Martucci, N, Manna, V, Conti, L, Fioravanti, M.Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer’s dementia: a neuropsychological and computerized electroencephalographic study. Clin Neuropharmacol 1983; 6: 311–323.CrossRefGoogle ScholarPubMed
127. Sebban, C.Quantified EEG: a possible tool for classification of SDAT and prediction of drug effects on cognition. Arch Gerontol Geriatr 1989; 1:237–240.Google Scholar
128. Perryman, KM, Fitten, LJ.Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 1991; 4: 127–133.CrossRefGoogle ScholarPubMed
129. Thatcher, R, Toro, C, Hatlett, M.Multimodal registration of EEG, PET, MRI; analysis of neural network switching. In: Proceedings of the Society of Magnetic Resonance in Medicine; functional MRI of the brain, June 17–19, Arlington VA, 1993; 171–181.Google Scholar
130. Gevins, A.High resolution EEG. Brain Topography 1993; 5: 321–325.CrossRefGoogle ScholarPubMed
131. Friden, PM, Walus, LR, Watson, P, Doctrow, SR, Kozarich, JW, et al. Blood brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993; 259: 373–377.CrossRefGoogle ScholarPubMed
132. Brooks, BR, Sanjak, M, Mitsumoto, H, Szirony, K, Neville, H, et al. Recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis (ALS) patients: phase 1-11 safety, tolerability, and pharmacokinetic studies. Neurology 1993; 43: A416.Google Scholar
133. Blass, JP.Pathophysiology of the Alzheimer’s syndrome. Neurology 1993; 43 (Suppl): S25–S38.Google Scholar
134. Goate, A, Chartier-Harlin, MC, Mullan, M.Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991; 349: 704–706.CrossRefGoogle ScholarPubMed
135. St. George-Hyslop, P, Tanzi, R, Polinsky, RJ.The genetic defect causing Alzheimer’s disease maps on chromosome 21. Science 1987; 235:885–890.CrossRefGoogle ScholarPubMed
136. Schellenburg, GD, Bird, TD, Wijsman, EM.Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 1992; 258: 668–671.CrossRefGoogle Scholar
137. St. George-Hyslop, P, Haines, JL, Farrer, LA.Genetic linkage studies suggest that Alzheimer’s disease is not a single homogeneous disorder. Nature 1990; 347: 194–197.CrossRefGoogle Scholar